You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Boehringer Ingelheim
Medtronic
Mallinckrodt
Baxter

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,364,485


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,364,485 protect, and when does it expire?

Patent 9,364,485 protects SERNIVO and is included in one NDA.

This patent has four patent family members in three countries.

Summary for Patent: 9,364,485
Title:Topical formulations comprising a steroid
Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Inventor(s): Ubaidulla; Udhumansha (Namakkal, IN), Kandavilli; Sateesh (Hyderbad, IN), Vairale; Ajay Sunil (Hyderbad, IN), Wayne; Jeffrey A. (Markham, CA), Nalamothu; Vijendra (Basking Ridge, NJ), Meghal; Mistry (Ahmedabad, IN), Pakunlu; Refika Isil (Highland Park, NJ)
Assignee: DR. REDDY'S LABORATORIES LTD. (Hyderabad, IN)
Application Number:13/391,972
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,364,485
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 9,364,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Encore Dermat SERNIVO betamethasone dipropionate SPRAY;TOPICAL 208079-001 Feb 5, 2016 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF PLAQUE PSORIASIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,364,485

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India2111/CHE/2009Aug 31, 2009
PCT Information
PCT FiledAugust 31, 2010PCT Application Number:PCT/US2010/047240
PCT Publication Date:March 03, 2011PCT Publication Number: WO2011/026076

International Family Members for US Patent 9,364,485

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2473161   Start Trial
Japan 2013503203   Start Trial
Japan 5833007   Start Trial
World Intellectual Property Organization (WIPO) 2011026076   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Johnson and Johnson
Mallinckrodt
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.